-
KICVentures Group acquires NanoFuse Biologics
Capital market company KICVentures Group has completed the acquisition of NanoFuse Biologics. -
Novartis' spinal muscular atrophy drug approved in Canada
Health Canada has approved Zolgensma for the treatment of pediatric spinal muscular atrophy patients with three or less copies of the SMN2 gene, or infantile-onset SMA. -
N2 Biomedical appoints new CEO
Eric Tobin has been announced as CEO of N2 Biomedical, a company providing coating and surface treatment for medical devices, according to a Dec. 2 press release. -
Stem cells in spine, orthopedics: 6 notes for surgeons
A landmark clinical trial was announced in November when a $9 million grant was provided for the first human study using stem cells to treat a spinal disorder that occurs in babies in the womb. -
California votes to boost stem cell research funding
Voters approved a proposition to provide $5.5 billion for stem cell research by the California Institute of Regenerative Medicine, according to a Nov. 13 press release. -
Stem cell agency awards $9M for landmark spina bifida clinical trial
The first human clinical trial using stem cells to treat spina bifida has been made possible thanks to a $9 million grant provided Nov. 12 by the California Institute for Regenerative Medicine. -
Spinal cord implant earns breakthrough device designation
CelluBridge, a spinal cord scaffold implant, has received the FDA's breakthrough device designation. -
Stem cell trial heals man's rotator cuff post-surgery
A man who had shoulder pain turned to stem cells to aid his recovery from rotator cuff surgery, according to a Nov. 11 report from ABC12. -
Cerapedics launches bone graft in Canada
Cerapedics' i-Factor+ Matrix is now available for surgical implantation in Canada. -
SeaSpine study validates pushback of cellular bone matrix products
Cells in cellular bone matrix products do not improve fusion or bone formation, according to results of a preclinical SeaSpine study published in The Journal of Bone and Joint Surgery. -
'Separating science from hope': AAOS' biologic initiative to inform surgeons of approval status
The American Academy of Orthopaedic Surgeons on Oct. 15 introduced the AAOS Biologics Dashboard to help physicians keep up to date with the approval status of biologic innovations. -
FDA warns stem cell clinic about marketing claims, unapproved uses
A Wisconsin stem cell clinic has been cautioned by the FDA for marketing intrathecal and intravenous injections of human stem cell and tissue-based products for a variety of neurologic conditions, according to the Regulatory Affairs Professionals Society. -
Biologica Technologies introduces product for bone regeneration
Orthobiologic company Biologica Technologies on Oct. 6 launched OsseoGen, a cellular bone matrix designed for bone regeneration. -
Aziyo Biologics hires CFO with 20+ years of experience
Regenerative medicine company Aziyo Biologics on Sept. 28 appointed Matthew Ferguson as CFO. -
$2M grant awarded to Histogen to study knee cartilage regeneration
Regenerative medicine company Histogen has received a $2 million grant to help fund a clinical trial for knee cartilage regeneration. -
Dr. Rick Placide implants 1st Signafuse strips during lumbar spinal fusion
Richmond, Va.-based VCU Health spine surgeon Rick Placide, MD, implanted the first Signafuse strips in a patient during a posterolateral lumbar fusion, according to a Sept. 2 news release. -
6 recent orthobiologic advancements in spine surgery
A number of emerging biologic technologies are currently being evaluated and launched in the spine field. Here are six key developments in the past month: -
1st patient treated in Kuros Biosciences spinal fusion trial
Orthobiologics company Kuros Biosciences has treated the first patient in its clinical trial evaluating Fibrin-PTH for transforaminal lumbar interbody fusion in patients with degenerative disc disease. -
Royal Biologics acquisition strengthens spinal fusion portfolio
Orthobiologics company Royal Biologics acquired the Fibrinet system from Vertical Spine Sept. 1. -
$50M raised by DiscGenics to support expansion plans, clinical trials
Biopharmaceutical company DiscGenics has raised $50 million in a Series C funding round, according to an Aug. 25 news release.
Page 13 of 36